Mark Cragg,
Professor and Chair in Experimental Cancer Biology, Centre for Cancer Immunology
Mark Cragg is Professor of Experimental Cancer Biology in the Cancer Sciences Unit of Southampton University Faculty of Medicine. His research focuses on understanding two main types of therapeutics – antibodies and small molecule inhibitors. Over the last decade, he has investigated many different therapeutic reagents such as rituximab, bexxar, imatinib, gefitinib, cetuximab and tarceva and has been involved in the development of next generation antibody reagents such as ofatumumab and obinutuzumab, as well as first in class novel antibodies such as BI-1206.
He has published >140 papers in reputed journals and is a member of several advisory and editorial boards.
|
|
|
